Tag: blog

Study Design

Considerations for the Design and Execution of Medical Device Trials

While clinical trials for medical devices have many similarities to those for pharmaceuticals, the regulatory evaluation of devices is distinct from that of drugs – and there are critical differences in the way the device trials are designed and executed. Here are a few of the key differences: Requirement for a clinical trial When studying...

Study Design

Premier Voices #1: Rare Oncology w/ Colin Hayward & Peter Larson

The inaugural edition of Premier Voices focuses on rare oncology drug development and takes a looks at: Using adaptive design to limit patient exposure to ineffective treatments and increase the overall likelihood of success Making the most of small and geographically dispersed patient populations Dealing with limitations such as a lack of defined biomarkers and baseline...

STARR 911: Understanding & Implementing the New Guidance at Your Site

Premier Research recently contributed to the STARR 911 initiative, a project of the STARR Coalition to provide actionable guidance for clinical researchers after identifying volunteers with suicidal leanings. This post provides more information on the process itself, which was presented earlier this year at the 2018 ASCP Annual Meeting in Miami. Background The primary goal...

STARR 911 Provides Clinical Researchers With Actionable Guidance for At-Risk Volunteers

Having a chronic condition increases the odds of suicide by 363%, and patients with mental illness are particularly at risk.[1] For individuals contacting sites about possible enrollment in a clinical trial, the call may be their first attempt to reach out for help – yet many do not receive the education and support that could...

Medical and Regulatory Affairs

Medical Device Trials: What You Need to Know About U.S. Regulations

While clinical investigations of medical devices and investigational drugs have their differences, what they do have in common is the goal of safeguarding the rights and welfare of study participants while bringing safe and effective products to market as quickly and efficiently as possible. Not all medical devices require a clinical trial, depending on their...

Consulting

Planning a Gene Therapy Trial? Ask an Expert — and Pay Attention

It’s been 46 years since researchers Theodore Friedmann and Richard Roblin published a landmark paper in the journal Science that posed a provocative question: “Gene therapy for human genetic disease?” And while clinical trials for gene therapy drugs have become much more common in the past 20 years — more than 2,400 had been conducted...

Medical and Regulatory Affairs

Safety First: Special Considerations for Medical Device Trials

Medical devices are ubiquitous — from thermometers, bandages, and dental floss to blood glucose meters, hearing aids, and complex implantables such as pacemakers. The latest cutting-edge examples even extend to apps on tablets and PCs that physicians use to help monitor and treat patients. To ensure the safety and efficacy of these devices, regulators expect...

Clinical Research: Phase 1 - Phase 4

Tackling Common Issues in Gene Therapy Trial Operationalization

Between navigating relatively uncharted territory and the practical limitations of most gene therapy delivery systems, ensuring successful clinical trials of these products is a serious challenge for even the most experienced researchers. Compounding this is the long-term nature of most gene therapy trials — it’s not unusual to have follow-up periods of a decade or more....

Consulting

A Strategic Partner, or a Vendor Looking to You for the Answers?

Your compound holds great promise, and your investors are banking on a breakthrough. Which do you pick to run your clinical trial — a CRO that will share the risks and work with you to reach a common goal or a vendor who’s waiting on you to have all the answers? Any capable CRO can provide...

Medical and Regulatory Affairs

The Guardrails of GMOs: Regulatory Considerations for Gene Therapy Trials

Like any new medical product, gene therapies must undergo rigorous approval processes. However, there are a number of additional regulations for gene therapies that don’t apply to conventional pharmaceuticals. This is especially true within the European Union. (It’s important to note that while most gene therapy studies are based in the U.S. and Europe — which...